Reading SLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SLS free→Reading SLS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SLS free→QuarterlyIQ Insights · SLS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2026 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Results of Operations and Financial Condition. On March 19, 2026, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Results of Operations and Financial Condition. As of December 31, 2025, SELLAS Life Sciences Group, Inc. (the “Company”) estimates that its unaudited cash and cash equivalents position was $71.8 million. This amount is unaudited and preliminary and is subject to the completion of financial closing procedures, including management’s reviews. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the year ended D…
Results of Operations and Financial Condition. On November 12, 2025, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Entry into a Material Definitive Agreement. On October 24, 2025, SELLAS Life Sciences Group, Inc. a Delaware corporation (the “Company”), entered into a Warrant Inducement Agreement (the “Inducement Agreement”) with holders (the “Holders”) of certain existing warrants (the “Existing Warrants”) to purchase shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. Pursuant to the Inducement Agreement, the Holders and the Company agreed that, subject to any applic…
Entry into a Material Definitive Agreement. On October 1, 2025, SELLAS Life Sciences Group, Inc. (the “Company”), as subtenant, entered into a Letter Agreement with Times Square Tower Associates LLC (the “Sublandlord”) relating to a certain sublease (as amended) of certain premises located at Times Square Tower, 7 Times Square, New York, New York (the “Sublease”). The Letter Agreement provides for the extension of the expiration date of the Sublease from September 30, 2026 to September 30, 20…
Unregistered Sale of Equity Securities. The information contained in
Entry into a Material Definitive Agreement. On September 10, 2025, SELLAS Life Sciences Group, Inc. a Delaware corporation (the “Company”), entered into a Warrant Inducement Agreement (the “Inducement Agreement”) with a holder (the “Holder”) of certain existing warrants (the “Existing Warrants”) to purchase shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company. Pursuant to the Inducement Agreement, the Holder and the Company agreed that, subject to any appli…
Results of Operations and Financial Condition. On August 12, 2025, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
Changes in Registrant’s Certifying Accountant On June 3, 2025, SELLAS Life Sciences Group, Inc.’s (the “Company”) independent registered public accounting firm, Moss Adams LLP (“Moss Adams”), merged with Baker Tilly US, LLP. The combined audit practices operate as Baker Tilly US, LLP (“Baker Tilly”). In connection with the merger, Moss Adams has resigned as the auditors of the Company and on June 3, 2025, the Audit Committee of the Company’s Board of Directors accepted the resignation of Moss…
Results of Operations and Financial Condition. On May 13, 2025, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended March 31, 2025 and providing a corporate update. A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.